Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 10.6b

Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009

Recipients with Intestine Transplants

  Discharge Regimen (w/ or w/o Steroids
Use)		 All
Tac Tac+ MMF Tac+ Aza Tac+ Siro Other
Functioning Graft with Immunosuppression Info at Discharge 529 170 4 65 19 787
% of All Regimens 67.2% 21.6% 0.5% 8.3% 2.4% 100.0%
Induction Drug
Atgam/NRATG/NRATS 0.6% 1.8% 0.0% 0.0% 5.3% 0.9%
OKT3 4.2% 47.1% 0.0% 9.2% 110.5% 16.4%
Thymoglobulin 12.5% 67.1% 0.0% 23.1% 226.3% 30.2%
Zenapax 8.1% 15.3% 0.0% 7.7% 100.0% 11.8%
Simulect 2.1% 1.2% 0.0% 1.5% 21.1% 2.3%
Campath 23.6% 1.2% 25.0% 7.7% 105.3% 19.4%
No Induction Drugs Recorded 53.3% 17.1% 75.0% 60.0% 57.9% 46.3%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.